EML4-ALK in non-small-cell lung cancer: The breathtaking progress from benchtop to Phase III clinical trial

Geoffrey Y. Ku, Gilberto De Lima Lopes

Research output: Contribution to journalReview article

Abstract

EML4-ALK is a fusion oncogene found in approximately 5% of patients with non-small-cell lung cancer. It was first discovered in 2007, and is found predominantly in those who never smoke or light smokers (≤10 pack/year tobacco history), younger patients and those with adenocarcinoma histology. It occurs almost exclusively in patients without mutations in K-ras or EGFR. Completed Phase I and II trials suggest significant clinical activity of an ALK kinase inhibitor, PF-02341066 (crizotinib), in patients with advanced non-small-cell lung cancer who harbor an ALK translocation. A Phase III evaluation of crizotinib versus chemotherapy in the second-line setting is ongoing.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalTherapy
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2011

Keywords

  • EML4-ALK
  • lung cancer
  • oncogene
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'EML4-ALK in non-small-cell lung cancer: The breathtaking progress from benchtop to Phase III clinical trial'. Together they form a unique fingerprint.

  • Cite this